Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis.

VanDyke RD, McPhail GL, Huang B, Fenchel MC, Amin RS, Carle AC, Chini BA, Seid M.

Ann Am Thorac Soc. 2013 Jun;10(3):205-12. doi: 10.1513/AnnalsATS.201209-082OC.

2.

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL.

N Engl J Med. 1999 Jan 7;340(1):23-30.

3.

Tobramycin inhalation powder in cystic fibrosis patients: response by age group.

Geller DE, Nasr SZ, Piggott S, He E, Angyalosi G, Higgins M.

Respir Care. 2014 Mar;59(3):388-98. doi: 10.4187/respcare.02264. Epub 2013 Aug 27.

4.

Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.

Tappenden P, Harnan S, Uttley L, Mildred M, Carroll C, Cantrell A.

Health Technol Assess. 2013 Dec;17(56):v-xvii, 1-181. doi: 10.3310/hta17560. Review.

5.

Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.

Mazurek H, Chiron R, Kucerova T, Geidel C, Bolbas K, Chuchalin A, Blanco-Aparicio M, Santoro D, Varoli G, Zibellini M, Cicirello HG, Antipkin YG.

Pediatr Pulmonol. 2014 Nov;49(11):1076-89. doi: 10.1002/ppul.22989. Epub 2014 Jan 24.

PMID:
24464974
6.

The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.

Tappenden P, Harnan S, Uttley L, Mildred M, Walshaw M, Taylor C, Brownlee K.

Pharmacoeconomics. 2014 Feb;32(2):159-72. doi: 10.1007/s40273-013-0122-x.

PMID:
24338264
7.

Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.

Nick JA, Moskowitz SM, Chmiel JF, Forssén AV, Kim SH, Saavedra MT, Saiman L, Taylor-Cousar JL, Nichols DP.

Ann Am Thorac Soc. 2014 Mar;11(3):342-50. doi: 10.1513/AnnalsATS.201310-352OC.

8.

A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.

Chuchalin A, Csiszér E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, Varoli G, Monici Preti PA, Mazurek H.

Paediatr Drugs. 2007;9 Suppl 1:21-31.

PMID:
17536872
9.

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.

Konstan MW, Geller DE, Minić P, Brockhaus F, Zhang J, Angyalosi G.

Pediatr Pulmonol. 2011 Mar;46(3):230-8. doi: 10.1002/ppul.21356. Epub 2010 Oct 20.

10.

Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.

Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L.

Pediatr Pulmonol. 2012 Jan;47(1):44-52. doi: 10.1002/ppul.21521. Epub 2011 Aug 3.

PMID:
21815282
11.

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.

Stanojevic S, Waters V, Mathew JL, Taylor L, Ratjen F.

J Cyst Fibros. 2014 Mar;13(2):172-8. doi: 10.1016/j.jcf.2013.09.002. Epub 2013 Oct 3.

12.

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.

Dasenbrook EC, Konstan MW, VanDevanter DR.

J Cyst Fibros. 2015 May;14(3):370-5. doi: 10.1016/j.jcf.2014.11.005. Epub 2014 Dec 11.

13.

Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.

Al-Aloul M, Nazareth D, Walshaw M.

J Aerosol Med Pulm Drug Deliv. 2014 Aug;27(4):299-305. doi: 10.1089/jamp.2013.1055. Epub 2013 Nov 12.

PMID:
24219814
14.

Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.

Schechter MS, Trueman D, Farquharson R, Higuchi K, Daines CL.

Ann Am Thorac Soc. 2015 Jul;12(7):1030-8. doi: 10.1513/AnnalsATS.201312-453OC.

PMID:
26053185
15.

Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, Monici Preti PA, Aryayev NL.

Paediatr Drugs. 2007;9 Suppl 1:11-20.

PMID:
17536871
16.

Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.

Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N.

Chest. 2007 Aug;132(2):562-8. Epub 2007 Jul 23.

PMID:
17646236
17.

Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF).

Harrison MJ, McCarthy M, Fleming C, Hickey C, Shortt C, Eustace JA, Murphy DM, Plant BJ.

J Cyst Fibros. 2014 Dec;13(6):692-8. doi: 10.1016/j.jcf.2014.04.004. Epub 2014 May 10.

18.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA.

J Cyst Fibros. 2015 Jul;14(4):507-14. doi: 10.1016/j.jcf.2014.12.013. Epub 2015 Jan 13.

19.

Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.

Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, Moorehead L, Montgomery AB, Geller DE; Phase 2 FTI Study Group.

Am J Respir Crit Care Med. 2012 Jan 15;185(2):171-8. doi: 10.1164/rccm.201105-0924OC. Epub 2011 Nov 17.

20.

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

Ryan G, Jahnke N, Remmington T.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD008319. doi: 10.1002/14651858.CD008319.pub2. Review.

PMID:
23235659

Supplemental Content

Support Center